Molecular theranostic based on esterase-mediated drug activation for hepatocellular carcinoma

Amit Sharma; Eun Joong Kim; Seokgyu Mun; Myung Sun Ji; Bong Geun Chung; Jong Seung Kim

doi:10.1016/j.dyepig.2018.12.026

Molecular theranostic based on esterase-mediated drug activation for hepatocellular carcinoma

Amit Sharma, Eun Joong Kim, Seokgyu Mun, Myung Sun Ji, Bong Geun Chung, Jong Seung Kim

Research output: Contribution to journal › Article › peer-review

12 Citations (Scopus)

Abstract

In past few years, cancer specific targeted drug formulations have shown some hope of improving the therapeutics with minimized associated side effects of chemotherapy. However, the benefits has proven modest due to lack of systems that can be assessed easily from parent drugs while maintaining the same features of cancer associated prodrug activation. We developed a small molecule-based, carboxylesterase responsive theranostic, EDOX, with tumor-specific enzymatic activation for targeted delivery of the anticancer drug, Doxorubicin (Dox), to hepatocellular carcinoma (HCC) cells. Easy synthetic access, physiological stability, tumor-selective activation, and sustained drug release make EDOX an excellent candidate for use as a next-generation drug delivery system for HCC.

Original language	English
Pages (from-to)	628-633
Number of pages	6
Journal	Dyes and Pigments
Volume	163
DOIs	https://doi.org/10.1016/j.dyepig.2018.12.026
Publication status	Published - 2019 Apr

Keywords

Cancer
Drug delivery system
Hepatocellular carcinoma
Targeted therapy
Theranostic

ASJC Scopus subject areas

Chemical Engineering(all)
Process Chemistry and Technology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.dyepig.2018.12.026

Cite this

@article{3ab0e6e56a2f4ef2a1329e3a1d2ff8d4,

title = "Molecular theranostic based on esterase-mediated drug activation for hepatocellular carcinoma",

abstract = "In past few years, cancer specific targeted drug formulations have shown some hope of improving the therapeutics with minimized associated side effects of chemotherapy. However, the benefits has proven modest due to lack of systems that can be assessed easily from parent drugs while maintaining the same features of cancer associated prodrug activation. We developed a small molecule-based, carboxylesterase responsive theranostic, EDOX, with tumor-specific enzymatic activation for targeted delivery of the anticancer drug, Doxorubicin (Dox), to hepatocellular carcinoma (HCC) cells. Easy synthetic access, physiological stability, tumor-selective activation, and sustained drug release make EDOX an excellent candidate for use as a next-generation drug delivery system for HCC.",

keywords = "Cancer, Drug delivery system, Hepatocellular carcinoma, Targeted therapy, Theranostic",

author = "Amit Sharma and Kim, {Eun Joong} and Seokgyu Mun and Ji, {Myung Sun} and Chung, {Bong Geun} and Kim, {Jong Seung}",

note = "Funding Information: This work was supported by the National Research Foundation of Korea ( CRI 2018R1A3B1052702 , J.S.K; 2017R1D1A1B04033453 , E.J.K). This research was also supported by BioNano Health-Guard Research Center funded by the Ministry of Science and ICT(MSIT) of Korea as Global Frontier Project (Grant number H- GUARD_2013M3A6B2078950 ( 2014M3A6B2060302 )). Publisher Copyright: {\textcopyright} 2018 Elsevier Ltd",

year = "2019",

month = apr,

doi = "10.1016/j.dyepig.2018.12.026",

language = "English",

volume = "163",

pages = "628--633",

journal = "Dyes and Pigments",

issn = "0143-7208",

publisher = "Elsevier BV",

}

TY - JOUR

T1 - Molecular theranostic based on esterase-mediated drug activation for hepatocellular carcinoma

AU - Sharma, Amit

AU - Kim, Eun Joong

AU - Mun, Seokgyu

AU - Ji, Myung Sun

AU - Chung, Bong Geun

AU - Kim, Jong Seung

N1 - Funding Information: This work was supported by the National Research Foundation of Korea ( CRI 2018R1A3B1052702 , J.S.K; 2017R1D1A1B04033453 , E.J.K). This research was also supported by BioNano Health-Guard Research Center funded by the Ministry of Science and ICT(MSIT) of Korea as Global Frontier Project (Grant number H- GUARD_2013M3A6B2078950 ( 2014M3A6B2060302 )). Publisher Copyright: © 2018 Elsevier Ltd

PY - 2019/4

Y1 - 2019/4

N2 - In past few years, cancer specific targeted drug formulations have shown some hope of improving the therapeutics with minimized associated side effects of chemotherapy. However, the benefits has proven modest due to lack of systems that can be assessed easily from parent drugs while maintaining the same features of cancer associated prodrug activation. We developed a small molecule-based, carboxylesterase responsive theranostic, EDOX, with tumor-specific enzymatic activation for targeted delivery of the anticancer drug, Doxorubicin (Dox), to hepatocellular carcinoma (HCC) cells. Easy synthetic access, physiological stability, tumor-selective activation, and sustained drug release make EDOX an excellent candidate for use as a next-generation drug delivery system for HCC.

AB - In past few years, cancer specific targeted drug formulations have shown some hope of improving the therapeutics with minimized associated side effects of chemotherapy. However, the benefits has proven modest due to lack of systems that can be assessed easily from parent drugs while maintaining the same features of cancer associated prodrug activation. We developed a small molecule-based, carboxylesterase responsive theranostic, EDOX, with tumor-specific enzymatic activation for targeted delivery of the anticancer drug, Doxorubicin (Dox), to hepatocellular carcinoma (HCC) cells. Easy synthetic access, physiological stability, tumor-selective activation, and sustained drug release make EDOX an excellent candidate for use as a next-generation drug delivery system for HCC.

KW - Cancer

KW - Drug delivery system

KW - Hepatocellular carcinoma

KW - Targeted therapy

KW - Theranostic

UR - http://www.scopus.com/inward/record.url?scp=85059112331&partnerID=8YFLogxK

U2 - 10.1016/j.dyepig.2018.12.026

DO - 10.1016/j.dyepig.2018.12.026

M3 - Article

AN - SCOPUS:85059112331

SN - 0143-7208

VL - 163

SP - 628

EP - 633

JO - Dyes and Pigments

JF - Dyes and Pigments

ER -

Molecular theranostic based on esterase-mediated drug activation for hepatocellular carcinoma

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this